Evidence map›Paper›PMID 26034622›Full record

ArticleNeuro-oncology practice2014

Culturally and linguistically diverse patient participation in glioma research.

Zarnie Lwin, Alexander Broom, Rasha Cosman, Ann Livingstone, Kate Sawkins, Phillip Good, Emma Kirby, Eng-Siew Koh, Elizabeth Hovey, COGNO CALD working group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zarnie LwinDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Alexander BroomDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Rasha CosmanDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Ann LivingstoneDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Kate SawkinsDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Phillip GoodDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Emma KirbyDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Eng-Siew KohDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
Elizabeth HoveyDepartment of Medical Oncology , Royal Brisbane and Women's Hospital, Brisbane, Australia (Z.L.); School of Social Science , University of Queensland, St. Lucia, Australia (A.B., E.K.); Cooperative Trials Group for Neuro-Oncology (COGNO) and NHMRC Clinical Trials Centre , University of Sydney, Sydney, Australia (R.C., A.L., K.S.,); Department of Palliative Care , Mater Health Services, South Brisbane, Australia (P.G.); Department of Radiation Oncology , Liverpool Hospital, Liverpool, Australia (E.-S.K.); University of New South Wales, Sydney, Australia (E.-S.K., E.H.); Department of Medical Oncology , Prince of Wales Hospital , Sydney, Australia (E.H.).
COGNO CALD working group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marginal communities, such as culturally and linguistically diverse (CALD) patients, have significantly lower rates of recruitment, accrual, and retention in cancer clinical trials. A combination of language and cultural barriers means that trial participation from CALD communities remains at suboptimal levels, which in turn favors research findings that are biased towards therapeutic effects or toxicities within the context of non-CALD populations. Here we outline some key challenges and implications for CALD patient participation in glioma research in countries such as Australia, where English is the language of governance and health services implementation. We highlight multistakeholder interventions to improve both investigator recruitment and participation of CALD communities in future glioma research, particularly in this era when global migration has come of age. Enhancing research participation of CALD communities ensures not only wider understanding of genetic heterogeneity to improve glioma outcomes but also equity in access to care.

Indexed as

culturally and linguistically diverse (CALD)gliomaresearch participation

Identifiers

PMID26034622
PMCPMC4369695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.